Product
AI AGENTS
AI APPLICATIONS
OTHERS
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
PatSnap Eureka Platform
Agents for IP
Agents for Engineering
Agents for Life Sciences
Agents for Materials
PatSnap Eureka Desktop
NEWAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisOpen Platform
NEWProfessional Services
Law Firms
Life Sciences
High-Tech
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
Frontier
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report How do FXR agonists, THRβ agonists, and ACC inhibitors differ in targeting MASH? Mechanistic analysis and pipeline combination strategy evidence.
Article | Report Meta-analysis comparing lecanemab and donanemab vs placebo across ADCOMS, CDR-SB, ADAS-Cog 14, and amyloid PET in early Alzheimer's disease. Full effect sizes, CIs, and heterogeneity data.
Article | Report DESTINY-Breast04's updated 32-month follow-up confirms T-DXd's OS and PFS benefit in HER2-low mBC, with key findings on ILD safety, ER-low subgroups, and ADC positioning.
Article | Report Analyse THRβ agonist selectivity SAR, hepatic uptake optimisation, ADME/PK profiles, and structural strategies that reduce cardiac and bone off-target effects vs non-selective THR agonists.
Article | Report Analyse asundexian's oxopyridine scaffold, sub-nanomolar FXIa potency (Ki 0.26 nM), >38,000-fold selectivity over Factor Xa and thrombin, and structural differentiation from DOAC chemical series.
Article | Report Voclosporin vs cyclosporine A: structural modifications, SAR patterns, nephrotoxicity reduction data, ADME/PK profile, and pharmacophore features in IgA nephropathy.
Article | Report Deep-dive into Tarlatamab (AMG 757) BiTE architecture: DLL3-binding SAR, CD3 affinity tuning, bivalency data, and how it outperforms earlier DLL3 bispecifics.
Article | Report Deep patent analysis of tezepelumab: CDR sequences, epitope binding data, Fc engineering for half-life extension, and structural differentiation from earlier anti-TSLP biologics.
Article | Report Long-term DESTINY-Breast04 data show T-DXd cuts death risk by 31–42% vs TPC across HR+, HR−, and ER-subgroups in HER2-low metastatic breast cancer.
Article | Report How to engineer polymer composites with high thermal conductivity and electrical insulation for power electronics: filler selection, hybrid architectures, and breakdown voltage strategies.
Article | Report PEM, alkaline, and solid oxide electrolyzer critical materials in 2026: iridium scarcity, patent trends, and the innovation pipeline shaping green hydrogen at scale.
Article | Report How to select and optimize polymer resin systems for low-dielectric 5G copper clad laminates. Dk/Df targets, filler design, and thermal stability strategies.
Article | Report Iptacopan and danicopan vs eculizumab and ravulizumab in PNH: mechanistic rationale for proximal vs terminal complement inhibition and EVH control evidence.
Article | Report How do sulfide, oxide, and polymer solid-state electrolytes compare in 2026? Ionic conductivity, stability, and patent trends analysed from 539 filings.
Article | Report Silicone, DLC, sol-gel ceramics, bio-based polymers, and plasma films mapped against PFAS performance benchmarks and 2025–2027 regulatory deadlines.